Search

Scholarly Works (1 results)

Article
Peer Reviewed

A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

Munster, Pamela;
Bergsland, Emily;
Kelley, Robin Kate;
Bendell, JC;
Kelley, RK;
Shih, KC;
Grabowsky, JA;
Jones, S;
Martin, T;
Infante, JR;
Mischel, PS;
Matsutani, T

UC San Francisco Previously Published Works (2015)

© 2015 American Cancer Society.BACKGROUND The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results. This phase 1 study investigated the mTORC1/mTORC2 inhibitor CC-223 in patients w